Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

被引：15

作者：

Kumar, S. K. ^{[1
]}

Ma, E. ^{[2
]}

Engebretson, A. E. ^{[1
]}

Buadi, F. K. ^{[1
]}

Lacy, M. Q. ^{[1
]}

Dispenzieri, A. ^{[1
]}

Duh, M. S. ^{[3
]}

Lafeuille, M-H ^{[3
]}

Lefebvre, P. ^{[4
]}

Cheng, W. Y. ^{[3
]}

Dea, K. ^{[4
]}

Rembert, D. ^{[5
]}

Patt, D. ^{[5
]}

Niculescu, L. ^{[2
]}

Quick, M. ^{[2
]}

Rajkumar, S. V. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN USA

[2] Millennium Pharmaceut Inc, Cambridge, MA USA

[3] Anal Grp Inc, Boston, MA USA

[4] Ltee, Grp Anal, Montreal, PQ, Canada

[5] McKesson Specialty Hlth, The Woodlands, TX USA

来源：

LEUKEMIA | 2016年 / 30卷 / 04期

关键词：

PHASE-II; INDUCTION; THERAPIES; SURVIVAL; IMPACT;

D O I：

10.1038/leu.2015.225

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：995 / 998

页数：5

共 16 条

[11] Light Chain-Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study [J].

Ludwig, Heinz ;

Adam, Zdenek ;

Hajek, Roman ;

Greil, Richard ;

Tothava, Elena ;

Keil, Felix ;

Autzinger, Eva Maria ;

Thaler, Josef ;

Gisslinger, Heinz ;

Lang, Alois ;

Egyed, Miklos ;

Womastek, Irene ;

Zojer, Niklas .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4635-4641

[12] Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study [J].

Moreau, Philippe ;

Pylypenko, Halyna ;

Grosicki, Sebastian ;

Karamanesht, Ievgenii ;

Leleu, Xavier ;

Grishunina, Maria ;

Rekhtman, Grigoriy ;

Masliak, Zvenyslava ;

Robak, Tadeusz ;

Shubina, Anna ;

Arnulf, Bertrand ;

Kropff, Martin ;

Cavet, James ;

Esseltine, Dixie-Lee ;

Feng, Huaibao ;

Girgis, Suzette ;

van de Velde, Helgi ;

Deraedt, William ;

Harousseau, Jean-Luc .

LANCET ONCOLOGY, 2011, 12 (05) :431-440

[13]

Petrucci Maria Teresa, 2013, Tumori, V99, pe193, DOI 10.1700/1361.15125

[14] Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial [J].

Reeder, C. B. ;

Reece, D. E. ;

Kukreti, V. ;

Chen, C. ;

Trudel, S. ;

Hentz, J. ;

Noble, B. ;

Pirooz, N. A. ;

Spong, J. E. ;

Piza, J. G. ;

Zepeda, V. H. J. ;

Mikhael, J. R. ;

Leis, J. F. ;

Bergsagel, P. L. ;

Fonseca, R. ;

Stewart, A. K. .

LEUKEMIA, 2009, 23 (07) :1337-1341

[15] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma [J].

Richardson, Paul G. ;

Weller, Edie ;

Lonial, Sagar ;

Jakubowiak, Andrzej J. ;

Jagannath, Sundar ;

Raje, Noopur S. ;

Avigan, David E. ;

Xie, Wanling ;

Ghobrial, Irene M. ;

Schlossman, Robert L. ;

Mazumder, Amitabha ;

Munshi, Nikhil C. ;

Vesole, David H. ;

Joyce, Robin ;

Kaufman, Jonathan L. ;

Doss, Deborah ;

Warren, Diane L. ;

Lunde, Laura E. ;

Kaster, Sarah ;

DeLaney, Carol ;

Hideshima, Teru ;

Mitsiades, Constantine S. ;

Knight, Robert ;

Esseltine, Dixie-Lee ;

Anderson, Kenneth C. .

BLOOD, 2010, 116 (05) :679-686

[16] Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data [J].

Teitelbaum, April ;

Ba-Mancini, Abbie ;

Huang, Hui ;

Henk, Henry J. .

ONCOLOGIST, 2013, 18 (01) :37-45

← 1 2 →